EBS Emergent BioSolutions Inc.

NYSE emergentbiosolutions.com


$ 9.11 $ -0.81 (-8.19 %)    

Thursday, 20-Nov-2025 16:31:17 EST
QQQ $ 584.62 $ -14.20 (-2.37 %)
DIA $ 458.30 $ -3.66 (-0.79 %)
SPY $ 652.19 $ -10.10 (-1.52 %)
TLT $ 89.30 $ 0.35 (0.39 %)
GLD $ 375.00 $ -0.11 (-0.03 %)
$ 9.08
$ 10.08
$ 9.01 x 960
$ 9.11 x 1
$ 9.07 - $ 10.22
$ 4.02 - $ 13.41
1,155,431
na
476.88M
$ 1.81
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-emergent-biosolutions-maintains-15-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Emergent BioSolutions (NYSE:EBS) with a Buy and maintains $15 ...

 emergent-biosolutions-secures-30m-barda-contract-to-supply-cyfendus-anthrax-vaccine-by-march-2026

Emergent BioSolutions Inc. (NYSE:EBS) today announced it has received a $30 million contract modification from the Biomedical A...

 emergent-biosolutions-files-for-mixed-shelf-of-up-to-250m

 -SEC Filing

 emergent-biosolutions-narrows-fy2025-sales-guidance-from-75000m-85000m-to-76500m-83500m-vs-80000m-est

Emergent BioSolutions (NYSE:EBS) narrows FY2025 sales outlook from $750.00 million-$850.00 million to $765.00 million-$835.00 m...

 emergent-biosolutions-q2-adj-eps-016-beats-072-estimate-sales-14090m-beat-10500m-estimate

Emergent BioSolutions (NYSE:EBS) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $(...

 emergent-biosolutions-publishes-comprehensive-review-on-brincidofovir-for-mpox-in-expert-review-of-anti-infective-therapy-journal

Emergent BioSolutions Inc. (NYSE:EBS) today announced the publication of a comprehensive review article, "Brincidofovir in ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION